VidPrevtyn Beta
Withdrawn
This medicine's authorisation has been withdrawn
COVID-19 Vaccine (recombinant, adjuvanted)
MedicineHumanWithdrawn
On Monday, 12 January 2026, between 07:00 and 10:00 CET (Amsterdam time), this website will be unavailable due to scheduled maintenance.
- Rolling review
- Application under evaluation
- CHMP opinion
- European Commission decision
Overview
The marketing authorisation for Vidprevtyn Beta has been withdrawn at the request of the marketing-authorisation holder.
Product information
Latest procedure affecting product information:II/0007/G
11/03/2024
This medicine’s product information is available in all official EU languages.
Select 'available languages' to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
Product details
- Name of medicine
- VidPrevtyn Beta
- Active substance
- SARS-CoV-2 prefusion Spike delta TM protein, recombinant (B.1.351 strain)
- International non-proprietary name (INN) or common name
- COVID-19 Vaccine (recombinant, adjuvanted)
- Therapeutic area (MeSH)
- COVID-19 virus infection
- Anatomical therapeutic chemical (ATC) code
- J07BN04
Pharmacotherapeutic group
VaccinesTherapeutic indication
VidPrevtyn Beta is indicated as a booster for active immunisation to prevent COVID-19 in adults who have previously received an mRNA or adenoviral vector COVID-19 vaccine (see sections 4.2 and 5.1 in product information document).
The use of this vaccine should be in accordance with official recommendations.
News on VidPrevtyn Beta
This page was last updated on